|
US4965188A
(en)
*
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
US5130238A
(en)
*
|
1988-06-24 |
1992-07-14 |
Cangene Corporation |
Enhanced nucleic acid amplification process
|
|
US5364866A
(en)
*
|
1989-05-19 |
1994-11-15 |
Hoechst-Roussel Pharmaceuticals, Inc. |
Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
|
|
GB9001181D0
(en)
*
|
1990-01-18 |
1990-03-21 |
Imp Cancer Res Tech |
Genetic assay
|
|
US5846717A
(en)
*
|
1996-01-24 |
1998-12-08 |
Third Wave Technologies, Inc. |
Detection of nucleic acid sequences by invader-directed cleavage
|
|
WO2000055624A2
(en)
|
1999-03-15 |
2000-09-21 |
Leyland Jones Brian |
Elisa kit for the determination of metabolic phenotypes
|
|
ID30355A
(id)
*
|
1999-04-07 |
2001-11-22 |
Pfizer Prod Inc |
Penggunaan inhibitor-inhibitor cyp2d6 dalam terapi kombinasi
|
|
US20010034023A1
(en)
*
|
1999-04-26 |
2001-10-25 |
Stanton Vincent P. |
Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
|
|
US6960439B2
(en)
*
|
1999-06-28 |
2005-11-01 |
Source Precision Medicine, Inc. |
Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
|
|
US7250252B2
(en)
|
1999-12-30 |
2007-07-31 |
David Aaron Katz |
Amplification based polymorphism detection
|
|
US7179597B2
(en)
*
|
2000-04-13 |
2007-02-20 |
Georgetown University |
Genetic diagnosis for QT prolongation related adverse drug reactions
|
|
US6761895B2
(en)
*
|
2000-04-17 |
2004-07-13 |
Yamanouchi Pharmaceutical Co., Ltd. |
Drug delivery system for averting pharmacokinetic drug interaction and method thereof
|
|
WO2001096604A2
(en)
*
|
2000-06-12 |
2001-12-20 |
Genicon Sciences Corporation |
Assay for genetic polymorphisms using scattered light detectable labels
|
|
US20020022254A1
(en)
|
2000-07-28 |
2002-02-21 |
Karl Guegler |
Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
|
|
WO2002044994A2
(en)
|
2000-11-30 |
2002-06-06 |
Third Wave Technologies, Inc. |
Systems and methods for detection assay ordering, design, production, inventory, sales and analysis for use with or in a production facility
|
|
GB0102841D0
(en)
|
2001-02-05 |
2001-03-21 |
Novartis Ag |
Organic compounds
|
|
US20030170176A1
(en)
*
|
2001-03-14 |
2003-09-11 |
Mcgill University |
Individualization of therapy with antipsychotics
|
|
WO2002099118A2
(en)
|
2001-06-05 |
2002-12-12 |
Genaissance Pharmaceuticals, Inc. |
Method of identifying a polymorphism in cyp2d6
|
|
US7195877B2
(en)
*
|
2001-07-20 |
2007-03-27 |
Bioventures, Inc. |
Cytochrome P450 genetic variations
|
|
EP1281755A3
(en)
*
|
2001-07-31 |
2003-06-18 |
Pfizer Products Inc. |
Variants of the human cyp2d6 gene
|
|
JP2005525292A
(ja)
|
2001-08-24 |
2005-08-25 |
アリックス セラピューティクス |
非酸化的に代謝される化合物および組成物、それらの合成経路、ならびに使用方法
|
|
JP2005504783A
(ja)
|
2001-08-31 |
2005-02-17 |
ノバルティス アクチエンゲゼルシャフト |
イロペリドン代謝産物の光学異性体
|
|
BRPI0213564B8
(pt)
*
|
2001-10-30 |
2021-05-25 |
Novartis Ag |
formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula
|
|
JP2005507261A
(ja)
|
2001-10-31 |
2005-03-17 |
ノバルティス アクチエンゲゼルシャフト |
Ｔｃｆ１遺伝子における多型に基づく糖尿病および関連状態の治療方法
|
|
DE60239634D1
(de)
|
2001-12-10 |
2011-05-12 |
Novartis Ag |
Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
|
|
US20040096874A1
(en)
*
|
2002-04-11 |
2004-05-20 |
Third Wave Technologies, Inc. |
Characterization of CYP 2D6 genotypes
|
|
US20040091909A1
(en)
*
|
2002-07-05 |
2004-05-13 |
Huang Doug Hui |
High throughput cytochrome P450 genotyping
|
|
GB0216416D0
(en)
|
2002-07-15 |
2002-08-21 |
Novartis Ag |
Organic compounds
|
|
AU2003247948A1
(en)
|
2002-07-18 |
2004-02-09 |
Bioventures, Inc. |
Cytochrome p450 genetic variations
|
|
JP5348840B2
(ja)
|
2003-02-20 |
2013-11-20 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
薬物を選択する方法
|
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
|
US20050032070A1
(en)
*
|
2003-08-05 |
2005-02-10 |
Sebastian Raimundo |
Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
|
|
US20080166357A1
(en)
*
|
2004-05-11 |
2008-07-10 |
Stefan Golz |
Diagnostics and Therapeutics for Diseases Associated with Dipeptidyl-Peptidase 6 (Dpp6)
|
|
WO2006039663A2
(en)
|
2004-09-30 |
2006-04-13 |
Vanda Pharmaceuticals, Inc |
Methods for the administration of iloperidone
|
|
US20100063093A1
(en)
*
|
2007-03-28 |
2010-03-11 |
Curt Wolfgang |
Methods for the administration of iloperidone
|
|
US20150259747A1
(en)
|
2007-03-29 |
2015-09-17 |
Vanda Pharmaceuticals Inc. |
Method of predicting a predisposition to qt prolongation
|
|
WO2008121899A2
(en)
*
|
2007-03-29 |
2008-10-09 |
Vanda Pharmaceuticals Inc. |
Method of predicting a predisposition to qt prolongation
|
|
WO2008144599A2
(en)
*
|
2007-05-18 |
2008-11-27 |
Vanda Pharmaceuticals Inc. |
Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
|
|
JP5535914B2
(ja)
|
2007-09-10 |
2014-07-02 |
ヴァンダ ファーマシューティカルズ インコーポレイテッド |
Ｓｎｐ遺伝子型に基づく抗精神病薬治療
|
|
CA2698534C
(en)
|
2007-09-10 |
2018-10-09 |
Vanda Pharmaceuticals, Inc. |
Prediction of qt prolongation based on snp genotype
|
|
US9074256B2
(en)
|
2009-04-06 |
2015-07-07 |
Vanda Pharmaceuticals, Inc. |
Method of predicting a predisposition to QT prolongation
|
|
JP5881597B2
(ja)
|
2009-04-06 |
2016-03-09 |
ヴァンダ ファーマシューティカルズ インコーポレイテッド |
Ｑｔ延長に対する素因を予測する方法
|
|
US9072742B2
(en)
|
2009-04-06 |
2015-07-07 |
Vanda Pharmaceuticals, Inc. |
Method of predicting a predisposition to QT prolongation
|
|
WO2010117931A1
(en)
|
2009-04-06 |
2010-10-14 |
Vanda Pharmaceuticals, Inc. |
Method of treatment based on polymorphisms of the kcnq1 gene
|
|
ES2533091T3
(es)
|
2009-05-15 |
2015-04-07 |
Vanda Pharmaceuticals Inc. |
Tratamiento antipsicótico basado en genotipo de SNP de DRD2 o ANKK1
|
|
CA2865845C
(en)
|
2012-03-14 |
2020-02-18 |
Vanda Pharmaceuticals Inc. |
An iloperidone metabolite for use in the treatment of psychiatric disorders
|
|
US11071728B2
(en)
|
2015-12-11 |
2021-07-27 |
Vanda Pharmaceuticals Inc. |
Treatment of schizophrenia
|
|
US11214827B2
(en)
|
2018-08-30 |
2022-01-04 |
Vanda Pharmaceuticals Inc. |
Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
|
|
US11607408B2
(en)
|
2019-10-15 |
2023-03-21 |
Vanda Pharmaceuticals Inc. |
Method of treatment of schizophrenia
|